Compare GSK plc (GSK) vs Kimberly Clark Corp (KMB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Kimberly Clark Corp — how do they compare? GSK plc trades at $46.5 (market cap $91.88B), while Kimberly Clark Corp trades at $97.59 (market cap $32.51B). The key difference: GSK plc is far larger — about 2.8× Kimberly Clark Corp's market cap, and Kimberly Clark Corp pays the higher dividend (5.24%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Kimberly Clark Corp for 93 Days on average.
| GSK | KMB | |
|---|---|---|
Market Cap | $91.88B | $32.51B |
Volume | 7,730,529 | 6,139,913 |
Sector | Health | Consumer Staples |
52-Week High | $61.18 | $121.44 |
52-Week Low | $43.24 | $93.05 |
Typical Hold Time | 93 Days | 93 Days |
Enterprise Value | $111.88B | $38.07B |
Dividend Yield | 3.9% | 5.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.54, down 1.02% with bearish technical signals but strong fundamentals including 29.73% ROE and consistent earnings beats. The company maintains robust profitability with 72.73% gross margins and is actively expanding its oncology pipeline through strategic partnerships. Recent developments include a $750M cancer therapy acquisition and advancing mRNA vaccine candidates.
GSK presents a mixed outlook with strong operational performance offset by technical weakness. Investment appeal lies in valuation multiples below industry averages and pipeline expansion, though risks include HIV patent expirations and manufacturing restructuring. Analyst consensus leans cautious with 55% hold ratings amid near-term headwinds.
Kimberly-Clark (KMB) trades at $97.74, up 1.31% on the day, with a bearish technical outlook and mixed fundamentals. Recent earnings show a Q2 2026 miss but beats in prior quarters, while revenue declined to $16.45B in 2025. The company maintains a strong dividend yield of over 5% with 54 consecutive years of increases, but cash flow trends raise sustainability questions amid its pending Kenvue acquisition.
KMB offers value with a P/E of 19.32 and analyst consensus target of $117.25, implying 20% upside, but risks include integration challenges from the Kenvue deal, litigation liabilities, and pressured cash flows. The stock's high ROE of 129.43% signals efficient capital use, yet investor sentiment is cautious due to near-term execution hurdles.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →
